The firm also said it is contemplating selling its therapeutics division, and appointed David Bench as its new CFO.
The company said that the decline in revenues reflected lower industry-wide reimbursement rates under PAMA.
The assay is based on the company's AmpiProbe technology, which uses fluorescent reporter-labeled primers and quencher-labeled primers to amplify DNA.
The case, which was originally being fought between Enzo and Hologic, was decided in favor of Becton Dickinson, Hologic's co-plaintiff.
The latest NYS Department of Health approval expands the company's CT/NG testing to samples from multiple relevant body sites.
The company's patent related to labeled nucleotides for use as diagnostic tools and as therapeutic agents has been invalidated.
The company's clinical services revenues were down 34 percent year over year while product revenues ticked up 7 percent.
Under the terms of the settlement, Enzo Life Sciences will receive $14 million in exchange for granting global licenses to Hologic and Grifols.
The company said that diagnostic testing volumes, product and royalty revenues, and clinical services revenues all fell year over year.
The index's 13 percent gain was below the 39 percent surge of 2017 but occurred despite the poor performance of index stocks in December.
ScienceInsider reports that rude and unprofessional paper reviewers are common and can have harmful effects.
The US Senate has confirmed Stephen Hahn as the next commissioner of the Food and Drug Administration, according to the New York Times.
CNBC reports Apple is partnering with Color Genomics to offer its employees free DNA screening for disease.
In Science this week: researchers use CRISPR tool to find gut microbiome molecules involved in immunity, and more.
